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Second, conditions associated with high IL-18 production may provide a direct link between autoinflammation and macrophage activation syndrome. Third, dysregulation of inflammatory and cell differentiation pathways in nonhematopoietic cells, such as aberrant calcium signaling and impaired endothelial or keratinocyte development, provide an understanding of organ specificity in autoinflammatory disorders. Many of these discoveries highlight the intricate interconnections between autoinflammation, autoimmunity, immunodeficiency, and lymphoproliferation and suggest ways in which we may better diagnose and treat autoinflammatory diseases.
Evolution of the concept of autoinflammation
Over the last 25 years, our expanding knowledge about diseases presenting with noninfectious, "sterile" inflammatory fever attacks has significantly changed our approach to treatment. In 1999, Kastner and colleagues suggested that molecular mechanisms other than autoimmunity must cause the known periodic fever syndromes, FMF and TRAPS [1] , and the concept of autoinflammation was proposed. Genetic discoveries in the clinic and basic innate immune discoveries at the bench supplemented each other, resulting in the identification of several disease-causing genes associated with excessive IL-1 signaling (NLRP3, MVK, IL1RN, etc.) and the extension of IL-1 blocking therapies to autoinflammatory diseases without a known genetic cause (e.g., periodic fevers, aphthous ulcer, pharyngitis, adenitis syndrome (PFAPA) and systemic onset juvenile idiopathic arthritis (SJIA)). The discovery of IL-1 dysregulation in common inflammatory disorders, like gout and atherosclerosis, triggered investigations on the role of IL-1 in these diseases [2] . The recently discovered autoinflammatory diseases discussed This article is a contribution to the Special Issue on The Inflammasome and Autoinflammatory Diseases -Guest Editors: Seth L. Masters, Tilmann Kallinich, and Seza Ozen in this review prompted a reevaluation of the IL-1-centric view of autoinflammation.
The clinical features of interferon-mediated autoinflammatory diseases
Excessive interferon (IFN) signaling has largely been associated with mobilizing the adaptive immune response against intracellular invaders. Given the ability of type I IFN to inhibit proliferation and "inflammatory" cytokine synthesis (most notably IL-1) [3] , the discovery of IFN dysregulation causing autoinflammatory phenotypes was unexpected. A prominent, persistent gene expression pattern of transcripts known to be induced by type I IFN signaling [4] , an "IFN signature," identifies presumed "interferon-mediated diseases" or interferonopathies. The IFN signature was first described in systemic lupus and seemed to fit with the paradigm of IFN (over)stimulating adaptive immunity, but subsequent work has uncovered direct effects of IFN on innate cells in lupus [5] . The recently discovered monogenic interferon-mediated diseases elucidate the inflammatory aspects of chronic, excessive IFN production. The interferonopathies are discussed in greater detail elsewhere in this volume (below and also in Tables 1 and 2) , and we review the clinical aspects of interferonopathies that help distinguish this group of disorders from IL-1-mediated diseases.
Systemic inflammation, panniculitis, and myositis due to proteasome defects (PRAAS/CANDLE) Loss-of-function mutations in PSMB8, and other proteasome components (our unpublished data), cause a group of diseases referred to as proteasome-associated autoinflammatory syndromes (PRAAS) or chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE). The disease is referred to in the literature as joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy (JMP) syndrome and Nakajo-Nishimura syndrome [6] [7] [8] [9] . Features can include recurrent fevers, skin manifestations ranging from annular erythema to erythema nodosum-like panniculitis, eyelid swelling, hepatomegaly, and mostly asymptomatic basal ganglia calcifications but rarely intellectual disability, myositis, and arthralgias with small joint contractures. The characteristic lipodystrophy may occur in areas of chronic rash, panniculitis, and/or myositis. Systemic inflammatory attacks occur more in childhood-onset disease. Although partially steroid-responsive, treatment of these patients is challenging and no single agent has thus far shown dramatic efficacy. Untreated, mortality is high due to uncontrolled inflammation and eventual organ failure [9] . PRAAS/CANDLE patients have a persistently high elevation of the IFN signature as well as high serum IL-6. Various autoantibodies are often detectable without a pattern between patients and in the absence of autoimmunity [7] [8] [9] . PSMB8 is a subunit of the immunoproteasome: a protein degradation complex induced by IFNs and essential for antigen presentation among other functions. The molecular mechanisms linking proteasome dysfunction to the high IFN signature remain unknown, but the unfolded protein response, other cellular stress responses, and abnormal cell death are all proposed mechanisms (refer to Brehm, Krueger review in this volume). By contrast, proteasome dysfunction caused by mutations in TPP2 results in T cell dysfunction and predominantly presents with immunodeficiency and infections [10] . Given the poor responses to known treatments, therapies blocking IFN signaling are being used in clinical studies (see below).
Vasculopathy, vasculitis, and interstitial lung disease with STING hyperactivity (SAVI)
We recently described a novel vasculopathy/vosculitis syndrome caused by gain-of-function mutations in TMEM173/ STING [11, 12] . STING-associated vasculopathy with onset in infancy (SAVI) patients develop severe small dermal vessel vasculitis/and microangiopathic thrombosis often early in life. A telangiectatic, ulcerative, or pustular rash develops mostly on acral surfaces, including the digits, earlobes, and nose, and often results in digital ischemia and auto-or surgical amputation. Many patients also develop progressive and potentially fatal interstitial lung disease. Myositis can develop and autoantibody production is common. CNS disease and cerebral calcifications are not typically seen in SAVI. Autoantibody production varies widely and is not associated with disease severity, which is likely modulated by additional genetic factors [10] .
STING is an adaptor molecule of the cytosolic DNA danger sensing machinery. It responds to the enzymatic product of the DNA sensor cGAS (but may also respond to DNA directly) by mobilizing a signaling program that results in IRF3 activation and IFNβ transcription. SAVI patients uniformly show persistently high IFN signatures in the blood.
A compassionate use study blocking IFN signaling in PRAAS/CANDLE and SAVI with the Janus Kinase (JAK) inhibitor baricitinib is ongoing (www.clinicaltrials.gov NCT01724580).
Subacute encephalomyelitis with cerebral calcifications and white matter disease due to cytosolic nucleotide dysregulation (AGS)
In Aicardi-Goutières syndrome (AGS), patients are rarely seen in autoinflammatory disease clinics. Their disease presentation usually mimics intrauterine/congenital infections. Patients can develop cerebrospinal fluid pleocytosis and basal ganglia calcification, resultant subacute weakness, spasticity, paresthesias, and long-term neurologic and cognitive defects [13, 14] . The genetic causes of AGS include lost enzymatic activities important for regulating intracellular DNA and RNA metabolism (reviewed elsewhere in this issue). The resulting accumulation of cytosolic nucleotides promotes cell stress and triggers danger sensing and type I interferon production. In addition to these loss-of-function mutations that cause AGS 1-6, gain-of-function mutations in a cytosolic RNA sensor IFIH1 (encoding MDA5) induce a highly variable AGS-like phenotype [15] . Non-CNS manifestations of AGS include chilblains-like rash or livedo reticularis and often occur after the onset of CNS disease [14] .
Although basal ganglion calcifications are seen in PRAAS/ CANDLE patients, CANDLE patients lack white matter disease and rarely present with seizure, suggesting that upregulation of the IFN pathway may vary in different organs in different interferonopathies. [16, 17] . However, a subset of patients lacking ISG15 who were immunized with Bacillus CalmetteGuérin (BCG) vaccine also showed a striking lack of response to IFNγ and developed recurrent, severe mycobacterial infections [16] . By contrast, patients bearing loss-of-function mutations in ACP5 (encoding tartrate-resistant acid phosphatase, or TRAP) develop a syndrome of axial bone dysplasia, cerebral calcifications, and immune dysregulation [18, 19] . These patients' peripheral blood also bears a strong IFN signature, and although they can develop childhood fevers, their inflammatory phenotype is dominated by autoantibody-mediated pathology (e.g., hemolytic anemia, autoimmune thyroiditis, systemic lupus).
A role for IL-18 in macrophage activation syndrome and autoinflammation
Twenty-five years ago, Kumar and colleagues connected a syndrome of fulminant macrophage activation with impaired perforin-granzyme-mediated cytotoxicity [20] . Since then, the disease known as hemophagocytic lymphohistiocytosis (HLH) includes several monogenic defects directly linked to defective cytotoxicity. Familial HLH (FHL) is generally interpreted as an immunodeficiency, as the sepsis-like symptoms are generally triggered by persistent viral infection, often Epstein-Barr virus (EBV) [21] . A clinically similar disorder, macrophage activation syndrome (MAS) that complicates rheumatic/autoinflammatory diseases like systemic juvenile idiopathic arthritis (sJIA) and Still's disease, shares common clinical features with HLH. Though partial impairment of cytotoxicity has been associated with MAS [22, 23] , the clinical assessment of NK function is hampered by wide assay variability and lack of specificity [24] . MAS flares are not clearly triggered by infection; thus, how perforin/granzyme mediated killing promotes MAS remains poorly understood.
Episodic fevers, enteropathy, and MAS due to NLRC4 hyperactivity (NLRC4-MAS)
The recent association of gain-of-function mutations in NLRC4 with MAS suggests common pathogenic pathways that lead to macrophage activation in HLH and MAS [25, 26] . The reported NLRC4-MAS patients have had variable, early-onset enterocolitis followed by recurrent febrile episodes. Severe episodes were triggered by sleep deprivation, emotional stress, and infection and were classic for MAS with pancytopenia, hepatitis, splenomegaly, and hyperferritinemia. Hemophagocytosis was variable, and defects in cytotoxicity were apparent only during disease flares. Episodes were responsive to corticosteroids and possibly inhibition of IL-1 [26] . All NLRC4-MAS patients had extraordinary elevation of serum IL-18 even during clinical quiescence, a finding also seen in sJIA/Still's disease patients at risk for MAS [27, 28] . NLRC4 is a cytosolic innate immune sensor that upon activation triggers the formation of an inflammasome. NLRC4 is homologous to NLRP3; the NLRP3 gene is mutated in cryopyrin-associated periodic syndromes (CAPS). Hyperactivity of either protein results in spontaneous inflammasome activation and excessive caspase-1-dependent cell death (pyroptosis). However, serum levels of IL-18 are 10-to 100-fold higher than in CAPS, and NLRC4-MAS macrophages appear uniquely primed for spontaneous IL-18 production [25, 26] . Notably, a mild familial cold-induced autoinflammatory syndrome (FCAS, a type of CAPS) phenotype was also associated with an activating NLRC4 mutation [29] . IL-18 levels in these patients were not tested.
NLRC4 hyperactivity may promote MAS in any of several ways (Fig. 1) . Excess inflammasome activity could directly promote macrophage-derived inflammation in the form of cytokine production, pyroptosis, and/or persistence. Chronic IL-18 overstimulation could promote excessive Th1-type responses by lymphocytes. Chronic IL-18 could also, paradoxically, impair NK cell development and function.
MAS, Crohn's disease, and other autoinflammatory phenotypes in XIAP deficiency
Deficiency of XIAP was originally described as an Xlinked risk factor for EBV-triggered HLH and was associated with NKT cell immunodeficiency [30] . However, several recent reports have suggested that XIAP deficiency may be better characterized as autoinflammatory. Only about half of XIAP-related HLH is triggered by EBV [31] . Likewise, defective cytotoxicity and other lymphocyte defects identified in FHL are not present in XIAP deficiency [31] . Furthermore, phenotypes suggestive of autoinflammation (particularly inflammatory bowel disease but also arthritis, erythema nodosum, periodic fevers, and uveitis) have recently been identified [32, 33] . Finally, as in MAS, patients with XIAP-related HLH have constitutive and extreme elevation of serum IL-18 [34] . XIAP performs many functions, and no single diseaseassociated pathway seems to correlate with its deficiency [35] . XIAP was originally found to inhibit apoptosis, but it is also critical for NOD2 signaling [36] and Crohn's disease and early-onset sarcoidosis/Blau syndrome have been associated with putative loss-and gain-offunction mutations in NOD2, respectively [37] . Additionally, murine studies suggest that XIAP-deficiency may promote inflammasome formation and hyperinflammation [38] . Thus, deficiency of XIAP results in a spectrum of clinical phenotypes with features of both immunodeficiency and autoinflammation, and attacks resulting in MAS.
New clinical phenotypes in diseases with mutations that largely affect tissue differentiation and/or immunity
This section includes four disorders that highlight novel mechanisms of autoinflammatory disease and tissue/ organ dysfunction (Fig. 2) .
Organ-specific defects that contribute to chronic inflammation
Keratinocyte-specific CARD14 hyperactivity (CAMPS)
In CARD14-mediated psoriasis (CAMPS), a genetic defect in nonhematopoietic cells results in innate cell recruitment and tissue-specific inflammation. CAMPS is caused by gain-of-function mutations in CARD14, which encodes an NF-kB activating scaffold protein downstream of protein kinase C [39, 40] . CARD14 expression is almost exclusive to keratinocytes, and CAMPS mutations result in IL-8, CCL20, and IL-36 secretion. CAMPS manifests as early-onset generalized pustulosis, plaque psoriasis, pityriasis rubra pilaris, and/or nail pitting [39] [40] [41] . Recurrent fevers have been reported but may be related to superinfected skin lesions. CAMPS patients may respond to inhibitors of the IL-17/23 pathway, similar to conventional psoriasis [42] .
Endothelial cell differentiation defect associated with vasculitis, stroke, fevers, and immune dysregulation due to ADA2 deficiency (DADA2)
Loss-of-function mutations in ADA2 result in deficiency of adenosine deaminase 2 (DADA2), a heritable form of early-onset vasculitis similar to polyarteritis nodosa [43, 44] . Severely affected patients develop early-onset recurrent fevers, livedoid or urticarial rash, low cell counts, hypogammaglobulinemia, hepatosplenomegaly, and small vessel vasculitis that can manifest as strokes but can also affect the coronary arteries, bowel, and kidneys. Systemic inflammation accompanies the fevers, and patient monocytes appear primed for inflammatory differentiation. Inhibition of TNFα or IL-6, or hematopoietic stem cell transplantation has been used to treat patients. Whereas deficiency of ADA1 results in the absence of lymphocytes and severe combined immunodeficiency, ADA2 appears critical for enabling alternative macrophage activation and normal endothelial development [43] ; both chronic inflammation and abnormal endothelial differentiation combine to promote the predilection for vasculitis. A syndrome of severe anemia with red blood cell mitochondrial iron deposits (sideroblasts), recurrent noninfectious fevers, B cell lymphopenia, hypogammaglobulinemia, variable immunodeficiency, and a variety of CNS insults (e.g., sensorineural hearing loss, but not basal ganglion calcification), and variable muscle weakness is caused by autosomal recessive mutations in TRNT1, encoding an enzyme critical for mitochondrial and cytosolic transfer-RNA synthesis [45] [46] [47] . Like other causes of sideroblastic anemia, TRNT1 deficiency impairs mitochondrial protein synthesis and causes cell stress related to the degree of enzymatic deficiency. This stress seems to impair neural and B cell development, while promoting inflammation, suggesting cell-type-specific effects. As in Hyper IgD Syndrome (mevalonate kinase deficiency) and other metabolic diseases, SIFD patients demonstrate another mechanism by which toxic buildup of enzymatic substrates can cause a complex inflammatory syndrome.
Signaling molecule dysfunction triggers autoinflammation and causes immunodeficiency
Cold-induced urticaria, atopy, and immune dysregulation due to alterations in PLCγ2 (PLAID)
Gain-of-function mutations in PLCγ2, a signaling molecule associated with increased calcium flux, result in PLCγ2- associated antibody deficiency and immune dysregulation (PLAID). All reported patients present with cold-induced urticaria, and many patients developed low immunoglobulins, atopy, granulomatous rash, sinopulmonary infections, autoantibodies, and/or autoimmunity [48] . The mutations appeared to increase the activity of this molecule specifically at cold temperatures, suggesting cold as a unique trigger for mast cell or other innate cell degranulation and inflammation. The inflammation of PLAID may partially involve the mutations' effects on baseline and stimulated intracellular calcium levels, which can serve as a trigger for the NLRP3 inflammasome [49] ; although a complete response to IL-1 inhibition has not been observed, IL-1 may be contributory. Overall, the mutation appeared to promote innate cell responses but blunt those in adaptive cells.
Summary
Novel monogenic autoinflammatory disorders continue to refine the concept of autoinflammation. We describe a new class of autoinflammatory diseases caused by excess IFN signaling that is characterized by vasculopathy, cerebral calcifications, variable pulmonary disease, and variable autoantibody formation. Although the mechanistic pathways that lead to overlapping innate and adaptive immune dysfunction need to be better characterized, there is the clinical need for measurement of IFN responses and clinical trials of drugs blocking the IFN-pathway. An autoinflammatory disease associated with MAS provides unexpected links between the inflammasome products IL-1β and IL-18, NF-kB activity, and cytotoxicity, suggesting novel targets for therapy. Future research must identify environmental and intrinsic sources of variation, identify new inflammatory mediators, and examine the basis for organ-specific inflammation. Rare monogenic autoinflammatory syndromes continue to not only provide insights into more common disorders but also inform how we understand and treat patients with excess inflammation.
